Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients

• Status: RECRUITING
• Trial end date: 2025-12-31

Summary

1.To explore the functional changes of P-gp, CYP3A4, OATP1B and BCRP in Diabetic patients (including the non-obese T2DM, obese T2DM, elderly T2DM, and T1DM).

• Phase: PHASE4

Details

• Lead Sponsor: Peking University Third Hospital
• Treatments: Dabigatran; Midazolam; pitavastatin; Rosuvastatin Calcium